Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Diego J Bedoya & Nicholas Mitsiades. (2013) Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. OncoTargets and Therapy 6, pages 9-18.
Read now
Read now
Shaista Hafeez & Christopher Parker. (2013)
Radium-223 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs 22:3, pages 379-387.
Read now
Read now
Articles from other publishers (18)
Tomasz M. Wróbel, Flemming Steen Jørgensen, Amit V. Pandey, Angelika Grudzińska, Katyayani Sharma, Jibira Yakubu & Fredrik Björkling. (2023) Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment. Journal of Medicinal Chemistry 66:10, pages 6542-6566.
Crossref
Crossref
Nur Erysha Sabrina Jefferi, Asma’ ‘Afifah Shamhari, Nur Khayrin Zulaikha Noor Azhar, Joyce Goh Yi Shin, Nur Annisa Mohd Kharir, Muhammad Afiq Azhar, Zariyantey Abd Hamid, Siti Balkis Budin & Izatus Shima Taib. (2023) The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches. Biomedicines 11:3, pages 826.
Crossref
Crossref
Alan Alfano, Jin Xu, Xi Yang, Dhanraj Deshmukh & Yun Qiu. (2022) SRC Kinase-Mediated Tyrosine Phosphorylation of TUBB3 Regulates Its Stability and Mitotic Spindle Dynamics in Prostate Cancer Cells. Pharmaceutics 14:5, pages 932.
Crossref
Crossref
Luca Filippi, Agostino Chiaravalloti, Pietro Basile, Orazio Schillaci & Oreste Bagni. (2022) Molecular and Metabolic Imaging of Castration-Resistant Prostate Cancer: State of Art and Future Prospects. Current Molecular Medicine 22:1, pages 25-36.
Crossref
Crossref
Tanzila Khan, Kieran F. Scott, Therese M. Becker, John Lock, Mohammed Nimir, Yafeng Ma & Paul de Souza. (2020) The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?. Prostate Cancer 2020, pages 1-16.
Crossref
Crossref
Vera Constâncio, Sandra P. Nunes, Rui Henrique & Carmen Jerónimo. (2020) DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types. Cells 9:3, pages 624.
Crossref
Crossref
Andrew K. Kwegyir-Afful, Senthilmurugan Ramalingam, Vidya P. Ramamurthy, Puranik Purushottamachar, Francis N. Murigi, Tadas S. Vasaitis, Weiliang Huang, Maureen A. Kane, Yuji Zhang, Nicholas Ambulos, Sudhir Tiwari, Pratima Srivastava, Ivo P. Nnane, Arif Hussain, Yun Qiu, David J. Weber & Vincent C. O. Njar. (2019) Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo. Cancers 11:11, pages 1637.
Crossref
Crossref
Helle D Zacho, Nita N Karthigaseu, Randi F Fonager & Lars J Petersen. (2016) Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review. BMJ Supportive & Palliative Care, pages bmjspcare-2015-000957.
Crossref
Crossref
Andrew K. Kwegyir-Afful, Senthilmurugan Ramalingam, Puranik Purushottamachar, Vidya P. Ramamurthy & Vincent C.O. Njar. (2015)
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts
in vivo
. Oncotarget 6:29, pages 27440-27460.
Crossref
Crossref
JGC van Hasselt, A Gupta, Z Hussein, JH Beijnen, JHM Schellens & ADR Huitema. (2015) Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin. CPT: Pharmacometrics & Systems Pharmacology 4:7, pages 386-395.
Crossref
Crossref
Maria José Ribal, Juan Ignacio Martínez-Salamanca & Camilo García Freire. (2015) Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain. Prostate Cancer 2015, pages 1-6.
Crossref
Crossref
R. Ouvinha de Oliveira, L.C. de Santa Maria & G. Barratt. (2014) Nanomedicine and its applications to the treatment of prostate cancer. Annales Pharmaceutiques Françaises 72:5, pages 303-316.
Crossref
Crossref
Dachuang Liu, Tao Tao, Bin Xu, Shuqiu Chen, Chunhui Liu, Lei Zhang, Kai Lu, Yeqing Huang, Liang Jiang, Xiaowen Zhang, Xiaoming Huang, Lihua Zhang, Conghui Han & Ming Chen. (2014) MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). Biochemical and Biophysical Research Communications 445:1, pages 151-156.
Crossref
Crossref
Yu Qin, Anindya Dey, Hamsa Thayele Purayil & Yehia Daaka. (2013) Maintenance of Androgen Receptor Inactivation by S-Nitrosylation. Cancer Research 73:22, pages 6690-6699.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Urology 23:3, pages 283-292.
Crossref
Crossref
Yeqing Angela Yang & Jindan Yu. (2013) EZH2, an epigenetic driver of prostate cancer. Protein & Cell 4:5, pages 331-341.
Crossref
Crossref
Kevin C. Soares, Lei Zheng, Barish Edil & Elizabeth M. Jaffee. (2012) Vaccines for Pancreatic Cancer. The Cancer Journal 18:6, pages 642-652.
Crossref
Crossref
Karina Dalsgaard Sørensen. (2012) Predicting the future of advanced prostate cancer. The Lancet Oncology 13:11, pages 1067-1068.
Crossref
Crossref